Skeletal Event Risk Factors in Bone mCRPC Identified

Share this content:
Several factors are predictive of skeletal-related events among patients being treated for bone metastatic castration-resistant prostate cancer.
Several factors are predictive of skeletal-related events among patients being treated for bone metastatic castration-resistant prostate cancer.

Several factors—such as bone pain and year of metastasis—are predictive of skeletal-related events (SREs) among patients being treated for bone metastatic castration-resistant prostate cancer (mCRPC), according to a study published in Cancer.1

Researchers evaluated data from 233 patients with non-metastatic CRPC who developed bone metastases during follow-up to determine factors predictive of SREs. Patients were a median age of 75 years at time of diagnosis.

At a median follow-up of 7.8 months, the researchers noted 88 patients who had an SRE.

A more recent year of metastasis, prostate-specific antigen doubling time of at least 9 months as opposed to less than 9 months, as well as bone pain were associated with SRE risk upon univariable analysis.

Year of metastasis, a biopsy Gleason score of at least 7, radiotherapy as the primary localized treatment, and bone pain were associated with SRE risk upon multivariable analysis.

RELATED: GATA2 in Prostate Cancer: A Promising Biomarker

“If confirmed, future trials should focus on prolonging life and reducing SRE risk in patients with mCRPC with bone pain,” the authors concluded.

Reference

  1. Klaassen Z, Howard LE, de Hoedt A, et al. Factors predicting skeletal-related events in patients with bone metastatic castration-resistant prostate cancer. Cancer. 2016 27 Dec. doi: 10.1002/cncr.30505 [Epub ahead of print]

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters